Journal article
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease
R Wolfe, JB Wetmore, RL Woods, JJ McNeil, H Gallagher, P Roderick, R Walker, MR Nelson, CM Reid, RC Shah, ME Ernst, JE Lockery, AM Tonkin, WP Abhayaratna, P Gibbs, EM Wood, SE Mahady, JD Williamson, GA Donnan, GC Cloud Show all
Kidney International | ELSEVIER SCIENCE INC | Published : 2021
Abstract
The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m2 or urine albumin to creatinine ratio 3 mg/mmol or more. In 4758 par..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank Nan Booth, MSW, MPH, ELS and Anne Shaw of the Chronic Disease Research Group for manuscript editing and preparation, respectively. This work was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (Grant U01 AG029824), the National Health and Medical Research Council of Australia (Project Grants 334047 and 1127060), Monash University, and the Victorian Cancer Agency.